GC Cell Administers First CAR-NK Treatment to Gastric and Gastroesophageal Junction Cancer Patients
Launch of Advanced Regenerative Medicine Clinical Study for Advanced HER2-Positive Patients
Evaluation of Safety and Initial Efficacy of HER2-Targeted Allogeneic CAR-NK Cell Therapy
GC Cell has begun clinical development targeting solid tumors by administering its HER2-targeted CAR-NK cell therapy, 'AB-201', to the first patient.
On May 19, GC Cell announced that AB-201 was administered for the first time to patients with advanced HER2-positive gastric cancer and gastroesophageal junction cancer as part of an advanced regenerative medicine clinical study led by Professor Jung Minkyu's research team at Severance Hospital.
This study aims to evaluate the safety and initial anti-tumor activity of AB-201 in patients with advanced HER2-positive cancer who have limited treatment options after standard therapies.
AB-201 is an allogeneic HER2-targeted CAR-NK cell therapy based on GC Cell's proprietary CAR-NK platform. It is a solid tumor pipeline designed to selectively attack tumor cells that overexpress HER2. Considering that previous CAR-NK development in Korea has primarily focused on hematologic malignancies, this first patient administration signifies the expansion of GC Cell's CAR-NK platform into solid tumors.
Professor Jung stated, "HER2-positive gastric cancer and gastroesophageal junction cancer are areas with high unmet medical needs even after standard treatments. Through this study, we plan to confirm the safety and clinical applicability of CAR-NK cell therapy."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
GC Cell CEO Won Sungyong said, "AB-201 is a key pipeline for expanding GC Cell's CAR-NK platform technology into the solid tumor field. With this first patient administration, we will accelerate the development of a new immunocellular therapy approach for patients with HER2-positive solid tumors and further advance AB-201 into a globally competitive cell therapy product."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.